The DOI matches its Crossref record.
Effect of piperine on the steady-state pharmacokinetics of phenytoin in patients with epilepsy
Abstract
Piperine, the active principle of Piper longum, Piper nigrum and Zingiber officinalis, has been reported to enhance the oral bioavailability of phenytoin in human volunteers. The objective of this study was to explore the effect of a single dose of piperine in patients with uncontrolled epilepsy on the steady‐state pharmacokinetics of phenytoin. Two groups of 10 patients each receiving either a 150 mg or 200 mg twice daily dose of phenytoin were selected. Twelve hours after the night dose, venous blood samples were collected at 0, 0.5, 1, 2, 4, 6, 9, 12 h after administration of phenytoin. On the next study day, piperine 20 mg was administered along with phenytoin and samples were collected similarly. The mean plasma drug concentrations at different time points and the pharmacokinetic parameters before and after piperine administration were compared by Student's t‐test. Piperine increased significantly the mean plasma concentration of phenytoin at most of the time points in both dose groups. There was a significant increase in AUC(0–12h) (p < 0.01), Cmax (p < 0.001) and Ka (p < 0.05) whereas the changes in Kel and tmax were not significant. The results showed that piperine enhanced the bioavailability of phenytoin significantly, possibly by increasing the absorption. Copyright © 2006 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Piperine also enhances the bioavailability of several other compounds including phenytoin, coenzyme Q10, theophylline, and propranolol (Bano et al., 1991; Badmaev et al., 2000; Pattanaik et al., 2006).”
From Curcuminoids Inhibit Multiple Human Cytochromes P450, UDP-Glucuronosyltransferase, and Sulfotransferase Enzymes, whereas Piperine Is a Relatively Selective CYP3A4 Inhibitor (2008) · cites this paper as Pattanaik et al., 2006
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 14
- Anand N, 1990, Comprehensive Medicinal Chemistry, 113
- Atal CK, 1985, Biochemical basis of enhanced drug availability of piperine: A potential inhibitory drug metabolism, J Pharm Exp Ther, 232, 258
- 10.1055/s-2006-962814 · DOI
- 10.1007/BF00314996 · DOI · Paper page
- 10.1006/phrs.1999.0640 · DOI
- Joshi MV, 1990, Simultaneous HPLC measurements of phenobarbitone, phenytoin and carbamazepine from plasma samples, Indian J Pharmacol, 22, 177
- 10.1078/0944-7113-00114 · DOI
- Khajuria A, 1998, Permeability characteristic of piperine on oral absorption – an active alkaloid from peppers as a bioavailability enhancer, Indian J Exp Biol, 36, 46
- Lowenstein DH, 2005, Harrison's Principle of Internal Medicine, 2357
- 10.1006/bbrc.1996.0100 · DOI
- Ritschel WA, 1999, Handbook of Basic Pharmacokinetics: Including Clinical Applications
- Singh J, 1986, Piperine mediated inhibition of glucuronidation in intestine: Evidence that piperine lowers the endogenous UDP‐glucuronic acid content, J Pharmacol Exp Ther, 236, 488
- 10.1007/BF03226378 · DOI
- Zutsi U, 1984, Influence of piperine on rifampicin blood levels in patients with pulmonary tuberculosis, J Assoc Physicians India, 33, 223
Cited by
Smith, A., Giunta, B., Bickford, P. C., Fountain, M., Tan, J., & Shytle, R. D. (2010) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2010.01.012 · Cited by 280
Volak, L. P., Ghirmai, S., Cashman, J. R., & Court, M. H. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020552 · Cited by 214
Gurley, B., Fifer, E., & Gardner, Z. (2012) · Planta Medica · doi:10.1055/s-0031-1298331 · Cited by 165
Clinically based evidence of drug–herb interactions: a systematic review
Kennedy, D. A., & Seely, D. (2010) · Expert Opinion on Drug Safety · doi:10.1517/14740330903405593 · Cited by 116
Metadata
- Authors
- Pattanaik, S., Hota, D., Prabhakar, S., Kharbanda, P., & Pandhi, P.
- Venue
- Phytotherapy Research
- Publisher
- Wiley
- Published
- 2006-06-12
- Volume
- 20
- Issue
- 8
- Pages
- 683-686
- ISSN
- 0951-418X
- 1099-1573
- Cited by
- 78
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
